TRENDS

Daiichi Sankyo Espha Sales Double as It Cashes In On Authorized Generic Boom

May 21, 2018
By Reiji Anasako The FY2017 earnings season saw a bonanza of authorized generics (AGs) as their major marketer, Daiichi Sankyo Espha, enjoyed sharp growth in its revenue, while original drug makers suffered steep sales declines in their flagship brands. The…

To read the full story

Related Article

TRENDS

By Takashi Ebisawa and Tatsuya Otsuka

Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…

By Takashi Ebisawa

Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…

By Yoshinori Sagehashi

Japan positions its new cost-effectiveness assessment (CEA) scheme merely as a tool to complement the current drug pricing system, but…

Tatsuya Kondo, chief executive of the Pharmaceuticals and Medical Devices Agency (PMDA), is hitting the exit at the end of…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

By Reiji Anasako

With Japan’s tighter price control casting a chill over its pharma market, companies are setting their sights beyond the field of health insurance to carve out a new revenue stream, seeking opportunities in the business to tackle “mibyo” - a…